Bacterial vaccines in clinical and preclinical development 2021: an overview and analysis
More vaccines must be developed to tackle antimicrobial-resistant (AMR) bacterial pathogens, and countries must make better use of the ones currently available, the WHO said in this report.
The World Health Organization’s (WHO) “An analysis of bacterial vaccines in preclinical and clinical development: 2021” is the first WHO analyses and report of vaccine candidates in preclinical and clinical development in 2021, in the context of antimicrobial resistance (AMR). The analyses focuses on vaccine candidates in development against pathogens in the WHO Bacterial Priority Pathogens list, Clostridioides difficile and Mycobacterium tuberculosis. The analysis highlights 61 vaccine candidates in various stages of clinical development, and 94 candidates in the preclinical development.